Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study

Peking Union Medical College Hospital ( Site 0105), Beijing

Beijing Cancer Hospital ( Site 0102), Beijing

Beijing Chest Hospital Capital Medical University ( Site 0111), Beijing

The First Hospital of Jilin University ( Site 0110), Changchun

Shanghai Chest Hospital ( Site 0112), Shanghai

Zhongshan Hospital Fudan University ( Site 0100), Shanghai

Jiangsu Cancer Hospital ( Site 0101), Nanjing

Anhui Provincial Hospital ( Site 0108), Hefei

The First Affiliated Hospital of Anhui Medical University ( Site 0113), Hefei

The First Affiliated Hospital Zhejiang University ( Site 0106), Hangzhou

Hangzhou First People's Hospital ( Site 0109), Hangzhou

2nd Affil Hosp of Zhejiang University College of Medicine ( Site 0114), Hangzhou

Zhejiang Cancer Hospital ( Site 0116), Hangzhou

Xiangya Hospital of Central South University ( Site 0115), Changsha

Hunan Cancer Hospital ( Site 0104), Changsha

1st Affil Hosp of Med College of Xi'an Jiaotong University ( Site 0103), XiAn

West China Hospital of Sichuan University ( Site 0117), Chengdu